At Daiichi Sankyo, we have a firm commitment to flexibility and transparency for all our alliances in service to making any collaboration greater than the sum of its parts. By creating tailored business models for each asset, we have built a history of strong, successful partnerships in the interest of rapidly bringing innovative therapies to patients. Our oncology pipeline is one of the strongest in the industry with great potential for transforming the way diseases are treated.
Our early research team focuses on new approaches to care, leveraging our world-class technology and expertise. Together with our partners, we believe we can transform standards of care.
- Early clinical assets or late preclinical in Breast, Lung and Colorectal Cancer
- Non-oncology, late-stage assets (Phase 2 ongoing or later) Regional Partnerships
- Immunology, Cardiovascular, CNS Diseases
Target areas, focusing on novel disease-relevant target identification research by using patient tissue samples or genetical analysis for the following target diseases
- Oncology: novel, unique, biologically tractable, tumor-associated antigens
- Immunology: refractory immune diseases and lung fibrosis
- Cardiovascular and Metabolic: heart failure, MASH (not TG reducer)
- CNS Diseases: neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, multiple system atrophy, and ALS and psychiatric diseases such as Schizophrenia
- Ophthalmology: AMD, RP, and PDR
Preferred modalities: Targeted Protein Degrader, Molecular Glue, RNA-targeting small molecules, siRNA delivery systems, bispecific/multi-specific antibodies and engineered protein technology platforms
- Oncology: novel, unique, biologically tractable, tumor-associated antigens
- Targeted Protein Degraders: Novel targeted protein degradation technologies such as tumor/tissue selective E3 ligases (other than CRBN, VHL, IAP or MDM2) and degradation mechanisms other than ubiquitin proteasome system (UPS)
- Molecular Glue: Novel methods for rational discovery of molecular glues in oncology and CNS
- RNA-targeting small molecule technologies: Novel strategies to modify translation, splicing, or other functionally relevant discovery methods
- siRNA delivery systems: delivery with priority for BBB-penetrant methods
- Bispecific/multi-specific antibodies and engineered protein technology platforms Technologies enabling functional or proximity-based bispecifics and engineered proteins with improved tumor selectivity and therapeutic index, including NKCE and TCE platforms
- ADC: focus on highly tumor specific targets and methods of discovering them
Modality agnostic asset enabling technologies: Binders or strategies for identifying novel, unique, biologically tractable, tumor-associated antigens, tumor microenvironment modulators, AI drug discovery
- Binders for novel, unique, biologically tractable, tumor-associated antigens: in single or multi-modal formats with improved therapeutic properties
- Tumor microenvironment modulators: e.g. TME-responsive biologics
- AI drug discovery: e.g. De novo design of protein-based binders
- Single cell proteomics, RNA-seq, and CTC biomarker based strategies
- Preclinical models for areas such as immune checkpoint inhibitor refractory tumors
Partner with us
Please contact us to start a conversation about how we can work together to improve patient lives. We have business development colleagues located globally, in Tokyo, Japan, the United States and in Europe. Please submit your confidential licensing or alliance proposal for consideration here: Submit non-confidential proposal